QL415
Cancer
Phase 1Active
Key Facts
About QLSF Biotherapeutics
QLSF Biotherapeutics is a private, clinical-stage biotech founded in 2020 and headquartered in South San Francisco, California. The company has built a robust pipeline of novel bispecific antibodies and cytokine fusion proteins targeting multiple immune-oncology mechanisms, with several programs already in Phase 1/2 clinical trials. Its strategy is driven by tumor biology, categorizing approaches for 'Myeloid Rich,' 'Immunologically Cold,' and 'Inflamed' tumor microenvironments. QLSF benefits from strong financial and clinical development support from a strategic partner, Qilu Pharmaceutical, which is advancing key assets in clinical studies.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |